Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101

PURPOSE: The ideal duration of adjuvant chemotherapy for patients with lower risk primary breast cancer is not known. Cancer and Leukemia Group B trial 40101 was conducted using a phase III factorial design to define whether six cycles of a chemotherapy regimen are superior to four cycles. We also s...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shulman, Lawrence N., Cirrincione, Constance T., Berry, Donald A., Becker, Heather P., Perez, Edith A., O'Regan, Ruth, Martino, Silvana, Atkins, James N., Mayer, Erica, Schneider, Charles J., Kimmick, Gretchen, Norton, Larry, Muss, Hyman, Winer, Eric P., Hudis, Clifford
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2012
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3494835/
https://ncbi.nlm.nih.gov/pubmed/22826271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.6405
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares